FDA May Revisit Accelerated Approval For Oncology Products
Executive Summary
FDA's oncology division is interested in revisiting the accelerated approval regulations as they apply to cancer treatments
You may also be interested in...
“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
A paradigm shift from maximum-tolerated dose to effective dose would result in more successful late-stage drug development, FDA Office of Clinical Pharmacology & Biopharmaceutics Pharmacometrics Team Leader Joga Gobburu, PhD, said April 23
“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
A paradigm shift from maximum-tolerated dose to effective dose would result in more successful late-stage drug development, FDA Office of Clinical Pharmacology & Biopharmaceutics Pharmacometrics Team Leader Joga Gobburu, PhD, said April 23
Millennium Velcade Multiple Myeloma Launch Expected In Late 2003
Millennium expects FDA approval of the proteasome inhibitorVelcade for multiple myeloma in the second half of 2003 based on Phase II data